ADA 2026 data showed that Caliway’s CBL-514 enhanced tirzepatide-induced weight loss, reduced post-treatment weight regain by 2.7-fold, and improved liver fat and insulin resistance markers in preclinical models.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
Caliway reported new preclinical findings at the American Diabetes Association (ADA) 2026 Scientific Sessions demonstrating that its investigational adipocyte-targeting therapy CBL-514 may enhance the efficacy and durability of GLP-1-based obesity treatments.
The data, presented by obesity and metabolic medicine expert Dr. Timothy Garvey, evaluated CBL-514 in combination with tirzepatide and showed greater weight-loss durability, reduced post-treatment weight regain, and additional metabolic benefits compared with tirzepatide alone.
The presentation drew attention from obesity researchers, clinical investigators, and pharmaceutical companies as the industry increasingly focuses on strategies that improve long-term weight maintenance after discontinuation of incretin-based therapies.
Addressing a Key Challenge in Obesity Treatment
While GLP-1 and dual GLP-1/GIP receptor agonists have transformed obesity management, substantial weight regain after treatment discontinuation remains a persistent clinical challenge.
The newly disclosed OI25 animal study examined whether adding CBL-514 could improve weight maintenance following cessation of tirzepatide therapy. Results showed that animals receiving tirzepatide alone regained 46.1% of lost weight after treatment discontinuation. In contrast, animals treated with the CBL-514 combination regained only 17.1% of lost weight.
The findings indicate a 2.7-fold reduction in post-treatment weight regain, suggesting that CBL-514 may help sustain weight-loss benefits beyond active treatment.
Metabolic Benefits Extend Beyond Weight Reduction
The study also demonstrated improvements across several metabolic parameters.
Animals receiving the CBL-514 and tirzepatide combination achieved an additional 106.7% reduction in hepatic lipid content compared with tirzepatide monotherapy. The combination regimen also produced notable improvements in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), a widely used measure of insulin sensitivity.
These findings suggest that the benefits of CBL-514 may extend beyond localized fat reduction and weight control into broader metabolic health outcomes, including liver fat reduction and insulin resistance.
CBL-514 Mechanism and Development Program
CBL-514 is a first-in-class small-molecule injectable therapy that selectively induces adipocyte apoptosis, reducing subcutaneous fat without damaging surrounding tissues. The candidate is being developed under the FDA’s 505(b)(1) pathway for indications including non-surgical fat reduction and cellulite, while a separate formulation, CBL-514D, is under development for Dercum’s disease.
More than 544 participants have received CBL-514 across clinical studies. According to the company, all primary and key secondary endpoints were achieved across 10 completed trials with finalized statistical reports, supporting the therapy’s safety, tolerability, and fat-reduction activity.
Building on Earlier Combination Studies
The OI25 results build on previous OI21 and OI23 preclinical studies evaluating CBL-514 alongside semaglutide and tirzepatide. Across those studies, combination treatment consistently enhanced weight loss, reduced subcutaneous and visceral fat accumulation, improved metabolic markers, and limited weight regain after treatment cessation.
The latest findings further strengthen the rationale for combining adipocyte-targeted therapies with incretin-based medicines as obesity treatment strategies continue to evolve.
Path Forward
Caliway plans to initiate human clinical studies evaluating CBL-514 in combination with GLP-1 receptor-based therapies during the second half of 2026. The company is also advancing global development and partnering initiatives as it seeks to expand the therapeutic potential of CBL-514 beyond aesthetic fat reduction into obesity and metabolic disease management.
Reference
About the Writer
Sana Jamil Khan (LinkedIn) is a B. Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.